Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292598 | 0.82 | PDE4B (0.37) | LMNAMAPTNPC1RAB9APDE4B | |
| Hydrochloric Acid SCHEMBL4284239 | 0.74 | L3MBTL1 (0.38) | RENNPC1RAB9AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL4281746 | 0.74 | REN (0.33) | LMNARENPIK3CDKMT2A | |
| SCHEMBL4298317 | 0.74 | CA1 (0.34) | RENMAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL4285826 | 0.74 | GAA (0.43) | LMNARENMAPTNPC1KDM4E | |
| Hydrochloric Acid SCHEMBL4292178 | 0.73 | CA1 (0.34) | RENMAPTNPC1RAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL4292918 | 0.73 | CYP1A2 (0.33) | LMNARENRAB9AKDM4EALDH1A1 | |
| SCHEMBL3261727 | 0.72 | RAB9A (0.50) | LMNAMAPTNPC1RAB9AKDM4E | |
| SCHEMBL4290889 | 0.72 | KDM4E (0.43) | RENMAPTKDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL4291908 | 0.72 | HPGD (0.44) | LMNAMAPTNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | LMNA 1785/4885REN 1/4885MAPT 3142/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | LMNA 1785/4885REN 1/4885MAPT 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.